Recent use of proton pump inhibitor-based triple therapies for the eradication of H pylori: a broad data review

Helicobacter. 2003 Apr;8(2):95-104. doi: 10.1046/j.1523-5378.2003.00129.x.

Abstract

Introduction: For the eradication of Helicobacter pylori a 1-week triple therapy combining proton pump inhibitors with two antibiotics has been recommended as a gold standard therapy. However, a recent broad data review on the efficacy of the different regimens is missing. Therefore, the aim of this study was to systematically review the recent literature.

Methods: We undertook a broad data review of the efficacy of nine different 7-day triple therapies consisting of a proton pump inhibitor (lansoprazole, pantoprazole, omeprazole) in its standard dosage and two antibiotics. Relevant original papers on H. pylori eradication in adults, published in English or German between 1995 and 2000, were identified from MEDLINE searches. Studies were reviewed and selected according to predefined criteria.

Results: Our predefined criteria were fulfilled by 79 full paper articles including 112 study arms with 8383 patients on intention-to-treat, or 6787 patients on per-protocol basis, respectively. The mean eradication rates unweighted or weighted by the number of patients in the study arm vary from 71.9% to 83.8% for intention-to-treat analysis and from 78.5% to 91.2% for per-protocol analysis.

Conclusions: All nine PPI based triple therapy regimens are very effective in H. pylori eradication. The current literature review underlines that the use of either lansoprazole, omeprazole, or pantoprazole combined with two antibiotics yield similar high eradication rates.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • 2-Pyridinylmethylsulfinylbenzimidazoles
  • Anti-Ulcer Agents / therapeutic use*
  • Benzimidazoles / therapeutic use
  • Clinical Trials as Topic
  • Helicobacter Infections / drug therapy*
  • Helicobacter pylori / drug effects*
  • Humans
  • Lansoprazole
  • Omeprazole / analogs & derivatives
  • Omeprazole / therapeutic use*
  • Pantoprazole
  • Proton Pump Inhibitors*
  • Sulfoxides / therapeutic use

Substances

  • 2-Pyridinylmethylsulfinylbenzimidazoles
  • Anti-Ulcer Agents
  • Benzimidazoles
  • Proton Pump Inhibitors
  • Sulfoxides
  • Lansoprazole
  • Pantoprazole
  • Omeprazole